Statin Treatment Improves Plasma Lipid Levels but not HDL Subclass Distribution in Patients Undergoing Percutaneous Coro
- PDF / 305,247 Bytes
- 11 Pages / 595.276 x 790.866 pts Page_size
- 72 Downloads / 181 Views
ORIGINAL ARTICLE
Statin Treatment Improves Plasma Lipid Levels but not HDL Subclass Distribution in Patients Undergoing Percutaneous Coronary Intervention Li Tian • Yucheng Chen • Chuanwei Li Zhi Zeng • Yanhua Xu • Shiyin Long • Mingde Fu
•
Received: 13 June 2012 / Accepted: 4 December 2012 / Published online: 29 December 2012 Ó AOCS 2012
Abstract Despite the established efficacy of statin therapy, the risk of cardiovascular events remains high in many patients. We examined high-density lipoprotein (HDL) subclass distribution profiles among statin-treated coronary heart disease (CHD) patients undergoing percutaneous coronary intervention (PCI). Plasma HDL subclasses were measured in 85 patients with established CHD and quantified by two-dimensional gel electrophoresis and immunoblotting. In CHD patients with statin treatment, the mean value of total cholesterol (TC) reached the desirable level and the triacylglycerol level (TAG) was borderline high. Moreover, low density lipoprotein cholesterol (LDL-C),
Li Tian and Yucheng Chen contributed equally to this study. L. Tian M. Fu Laboratory of Endocrinology and Metabolism, West China Hospital, Sichuan University, Chengdu 610041, Sichuan, People’s Republic of China L. Tian M. Fu (&) State Key Laboratory of Biotherapy, Sichuan University, Room 902, New building 6, #16 Section 3, People Road South, Chengdu 610041, Sichuan, People’s Republic of China e-mail: [email protected] Y. Chen C. Li Z. Zeng Cardiovascular Department, West China Hospital, Sichuan University, Chengdu 610041, Sichuan, People’s Republic of China Y. Xu Chengdu Hoist Biotechnology Co., Ltd., Sichuan, People’s Republic of China S. Long Department of Biochemistry and Molecular Biology, University of South China, Hengyang, Hunan, People’s Republic of China
high density lipoprotein cholesterol (HDL-C), apolipoproteinA-I, and apolipoproteinB-100 levels in these patients resembled those in normolipidemic healthy subjects. The HDL subclass did not show a normal distribution and was characterized by the lower large-sized HDL2b contents and higher contents of small-sized preb1-HDL in CHD patients, compared to those in normolipidemic control subjects. Multiple stepwise regression analysis revealed that the severity of coronary stenosis, determined by the Gensini Score, was significantly and independently predicted by HDL2b and HDL3b. Statin therapy was effective in modifying plasma lipids levels, but not adequate as a monotherapy to normalize the HDL subclass distribution phenotype of patients with CHD undergoing PCI. The HDL subclass distribution may aid in risk stratification, especially in patients with CHD and therapeutic LDL-C and HDL-C levels. Keywords Coronary heart disease High-density lipoprotein subclasses Statins therapy Quantitative coronary angiography Two-dimensional gel electrophoresis-immunodetection Abbreviations HDL CHD PCI QCA TC TAG LDL-C HDL-C ApoA-I ApoB-100 AMI
High density lipoprotein Coronary heart disease Percutaneous coronary intervention Quantitative co
Data Loading...
